Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386

1.

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L.

Br J Cancer. 2012 Mar 13;106(6):1160-5. doi: 10.1038/bjc.2012.41. Epub 2012 Feb 23.

2.

The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.

Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.

Cancer. 2004 Jun 1;100(11):2317-27.

3.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

4.

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.

Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):183-9. doi: 10.1016/j.clon.2011.09.008. Epub 2011 Sep 29.

PMID:
21958729
5.

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.

Clin Cancer Res. 2005 Mar 15;11(6):2163-8.

6.

Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.

Zhou W, Jirström K, Amini RM, Fjällskog ML, Sollie T, Lindman H, Sørlie T, Blomqvist C, Wärnberg F.

BMC Cancer. 2013 Oct 30;13:512. doi: 10.1186/1471-2407-13-512.

7.

[Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].

Polgár C, Orosz Z, Kahán Z, Gábor G, Jani N, Cserni G, Hadijev J, Kulka J, Sulyok Z, Boross G, Lázár G, László Z, Diczházi C, Udvarhelyi N, Szabó E, Péntek Z, Major T, Fodor J.

Magy Onkol. 2008 Sep;52(3):269-77. doi: 10.1556/MOnkol.52.2008.3.4. Hungarian.

PMID:
18845497
8.

Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.

Zhou W, Jirström K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Wärnberg F.

BMC Cancer. 2010 Nov 30;10:653. doi: 10.1186/1471-2407-10-653.

9.

Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, Pilotti S, van de Vijver MJ.

Br J Cancer. 2001 Feb;84(4):539-44.

10.

Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fernö M; South Sweden Breast Cancer Group.

Eur J Cancer. 2001 Aug;37(12):1514-22.

PMID:
11506959
11.
12.

Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy.

Rakovitch E, Pignol JP, Hanna W, Narod S, Spayne J, Nofech-Mozes S, Chartier C, Paszat L.

J Clin Oncol. 2007 Dec 10;25(35):5591-6. Epub 2007 Nov 5.

13.

Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.

Vargas C, Kestin L, Go N, Krauss D, Chen P, Goldstein N, Martinez A, Vicini FA.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1514-21. Epub 2005 Jul 11.

PMID:
16005576
14.

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.

de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J.

Histopathology. 2007 Aug;51(2):227-38.

PMID:
17650217
15.

Molecular phenotypes of DCIS predict overall and invasive recurrence.

Williams KE, Barnes NL, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ.

Ann Oncol. 2015 May;26(5):1019-25. doi: 10.1093/annonc/mdv062. Epub 2015 Feb 12.

16.

Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.

Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, Van Marck E, Weyler J, Praet M, Van den Broecke R, Vermorken JB, Tjalma WA.

Breast J. 2009 Mar-Apr;15(2):120-32. doi: 10.1111/j.1524-4741.2009.00686.x.

PMID:
19292797
17.

Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.

Solin LJ, McCormick B, Recht A, Haffty BG, Taylor ME, Kuske RR, Bornstein BA, McNeese M, Schultz DJ, Fowble BL, Barrett W, Yeh IT, Kurtz JM, Amalric R, Fourquet A.

Cancer J Sci Am. 1996 May-Jun;2(3):158-65.

PMID:
9166516
18.

Biological Markers Predictive of Invasive Recurrence in DCIS.

Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W.

Clin Med Oncol. 2008;2:7-18. Epub 2008 Jan 22.

19.

Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.

Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG.

Cancer. 2003 Mar 15;97(6):1393-403.

20.
Items per page

Supplemental Content

Write to the Help Desk